Discovery Labs reports trial data
May 14, 2015 at 19:11 PM EDT
Discovery
Laboratories Inc. (Nasdaq: DSCO) reported encouraging data from a Phase 2a
clinical trial of AEROSURF and will proceed to a Phase 2 clinical
program but the stock price fell 23 cents to close at $0.92.
